logo
LIC-backed NBFC raises ₹2,000 crores via QIP; Quant Mutual Fund ups stake to 5.96%

LIC-backed NBFC raises ₹2,000 crores via QIP; Quant Mutual Fund ups stake to 5.96%

Mint4 days ago

Capri Global Capital shares fell more than 5% during the early part of Monday's trading session; however, the stock has bounced back in the latter half of the session today. According to Rajesh Bhosale, Equity Technical and Derivative Analyst at Angel One, Capri Global Capital shares highly volatile counter witnessing sharp swings on both sides.
After a gap-down start today, the stock recovered to trade flat. The recent low near ₹ 150 acts as strong support, while a breakout above ₹ 185 and the 200DMA could trigger positive momentum. Traders should wait for a decisive move beyond the ₹ 150– ₹ 185 range.
Capri Global Capital share price today opened at ₹ 167.65 apiece on the BSE, the stock touched an intraday high of ₹ 172.60 per share, and an intraday low of ₹ 161.50 per share.
As per shareholding pattern public shareholder for the quarter ending 12 June 2025 on the BSE, Life Insurance Corporation Of India (LIC) holds 7.89% stake in Capri Global Capital. Sbi Life Insurance Co too holds 2.97% stake in the firm. In its most recent filing, the company announced that Quant Mutual Fund raised its stake to 5.96% from 1.53%.
The non-banking financial company (NBFC) has announced that it successfully completed its Qualified Institutional Placement (QIP), raising primary equity capital of ₹ 2,000 crores by issuing approximately 136.5 million shares to institutional buyers.
The QIP Committee, authorized by the Board, met on June 12, 2025, to determine the pricing and allocation for the QIP.
As stated in an exchange filing, this is the company's first QIP in the past ten years. The offering received an enthusiastic response from a diverse group of institutional investors, including both foreign and domestic long-only funds, mutual funds, and insurance companies such as Quant Mutual Fund, 3P Investment, BlackRock, Think Investments, Allspring Global Investments, ICICI Prudential Life Insurance, HDFC Life Insurance, ICICI Lombard General Insurance, SBI General Insurance, HDFC ERGO General Insurance, TATA AIF, and many other long-only investors, underscoring the company's execution and technological capabilities, strong governance, and long-term vision.
'The successful QIP marks a significant milestone in Company's growth journey. The capital raised will enable us to capitalise on growth opportunities across key lending verticals, expand our geographical presence, invest in AI & data science capabilities and strengthen our capital base,' said Rajesh Sharma, Managing Director of the company.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Biocon closes ₹4,500 crore QIP to boost innovation, expand global access
Biocon closes ₹4,500 crore QIP to boost innovation, expand global access

Business Standard

time2 hours ago

  • Business Standard

Biocon closes ₹4,500 crore QIP to boost innovation, expand global access

Biocon Ltd announced on Friday that it has successfully raised ₹4,500 crore through a qualified institutions placement (QIP), marking its first equity fundraising since its initial public offering in 2004. In a regulatory filing, the company stated it had issued over 136.3 million equity shares, each with a face value of ₹5, to eligible institutional investors. The shares were priced at ₹330 per unit, which includes a premium of ₹325. The QIP was open from June 16 to 19, 2025, and received strong interest from both Indian and global investors. Biocon said this response reflects growing confidence in the company's long-term strategic vision. Capital to support innovation and access to affordable healthcare 'The strong response to our QIP reflects deep investor conviction in Biocon's differentiated strategy and consistent execution,' said Siddharth Mittal, CEO and Managing Director of Biocon Ltd. 'This capital raise further strengthens our balance sheet, enabling us to invest in innovation, expand global access to lifesaving biopharmaceuticals, and advance our purpose of delivering affordable healthcare solutions that address pressing health inequities worldwide,' Mittal added. Proceeds allocated for strategic and financial needs Biocon stated that part of the capital raised will be used to purchase outstanding optionally convertible debentures of its subsidiary, Biocon Biologics Limited, from Goldman Sachs India AIF Scheme - 1 and Goldman Sachs India Alternative Investment Trust AIF Scheme - 2. Additionally, the funds will be used to repay, pre-pay, or redeem certain borrowings and financial instruments, and meet other financial requirements, including general corporate expenses.

Markets snap 3-day losing run; Sensex jumps 1,000 pts as financial, telecom shares gain
Markets snap 3-day losing run; Sensex jumps 1,000 pts as financial, telecom shares gain

The Print

time2 hours ago

  • The Print

Markets snap 3-day losing run; Sensex jumps 1,000 pts as financial, telecom shares gain

The 50-share NSE Nifty climbed 319.15 points or 1.29 per cent to 25,112.40. A largely supportive trend overseas and renewed foreign capital inflows supported domestic equities following signs of easing tension in the Middle East, traders said. After a flat start, the BSE Sensex later found its mojo back and surged 1,046.30 points or 1.29 per cent to settle at 82,408.17. During the day, it jumped 1,132.62 points or 1.39 per cent to 82,494.49. Mumbai, Jun 20 (PTI) Equity benchmark indices Sensex and Nifty rebounded sharply by over 1 per cent on Friday after sliding for the past three sessions, propelled by bargain hunting in financial, telecom and tech stocks amid a correction in global crude prices. As many as 2,463 stocks advanced while 1,484 declined and 147 remained unchanged on the BSE. This week, the BSE benchmark gauge jumped 1,289.57 points or 1.58 per cent, and the Nifty surged 393.8 points or .59 per cent. 'Equity indices surged as Middle East tension moderated with risk of immediate military actions reduced as US dialogue with Iran is expected to take place. The development led the crude price to correct, favouring domestic markets and boosting foreign investors' sentiments. 'In the broader market, rapid fall in VIX index and buying was witnessed in rate sensitives and consumer-oriented sectors like Finance, Auto and Reality and in anticipation of better Q1FY26 results led by rate cuts benefits, drop in inflationary pressure and rebound in consumer spending,' Vinod Nair, Head of Research, Geojit Investments Limited, said. From the Sensex firms, Bharti Airtel, Nestle, Mahindra & Mahindra, Power Grid, Reliance Industries, NTPC, Eternal and HDFC Bank were among the biggest gainers. In contrast, Maruti was the only laggard. The BSE midcap gauge jumped 1.20 per cent, and smallcap index climbed 0.55 per cent. All BSE sectoral indices ended higher. Telecommunication surged 2.73 per cent, realty (2.22 per cent), teck (1.42 per cent), capital goods (1.17 per cent), bankex (1.15 per cent), consumer discretionary (1.12 per cent) and metal (1.10 per cent). 'Sentiment improved after the news report indicated a possible de-escalation in the Iran-Israel conflict, with the US signalling a delay in potential action, which led to a softening in crude oil prices. Additionally, consistent buying by FIIs in the cash segment further supported the market,' Ajit Mishra – SVP, Research, Religare Broking Ltd, said. In Asian markets, South Korea's Kospi and Hong Kong's Hang Seng settled in positive territory, while Japan's Nikkei 225 index and Shanghai's SSE Composite index ended lower. Markets in Europe were trading higher in mid-session trade. US markets were closed on Thursday for the Juneteenth holiday. Global oil benchmark Brent crude dropped 1.93 per cent to USD 77.33 a barrel. Foreign Institutional Investors (FIIs) bought equities worth Rs 934.62 crore on Thursday, according to exchange data. Domestic Institutional Investors (DIIs) also bought equities worth Rs 605.97 crore. On Thursday, the 30-share BSE Sensex declined 82.79 points, or 0.10 per cent, to settle at 81,361.87. The Nifty dipped 18.80 points or 0.08 per cent to 24,793.25. 'In the absence of any major domestic events, global markets will continue to guide sentiment. We maintain our positive yet cautious stance and advise focusing on stock selection, particularly in line with sectoral trends,' Mishra said. PTI SUM SUM BAL BAL This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Nippon India MF, BlackRock, others buy 10% stake in Sai Life for ₹1,505 cr
Nippon India MF, BlackRock, others buy 10% stake in Sai Life for ₹1,505 cr

Business Standard

time3 hours ago

  • Business Standard

Nippon India MF, BlackRock, others buy 10% stake in Sai Life for ₹1,505 cr

Nippon India Mutual Fund, BlackRock, Societe Generale, Morgan Stanley and others on Friday collectively bought a 10 per cent stake in Sai Life Sciences from US-based asset manager TPG for Rs 1,505 crore through open market transactions. Besides, Axis Mutual Fund (MF), Aditya Birla Sun Life MF, Invesco MF, Norway's Government Pension Fund Global, German multinational Allianz's arm Pimco, Axis Max Life Insurance, HDFC MF, Ghisallo Master Fund LP, UTI MF, DSP MF were among the buyers of Sai Life Sciences shares. These entities picked up more than 2.08 crore equity shares or 10 per cent stake in Hyderabad-based Sai Life Sciences, as per the block deal data on the BSE. The transaction, valued at around Rs 1,504.75 crore, was executed at an average price of Rs 722 apiece. Meanwhile, Nippon India MF picked up 49.86 lakh shares or 2.39 per cent holding in Sai Life Sciences. After the stake buy, Nippon India MF's stake in the company rose to 4.88 per cent from 2.48 per cent. Meanwhile, global asset manager TPG through its affiliate TPG Asia VII SF offloaded the equal number of shares in 25 tranches at the same price. Following the stake sale, TPG's holding in Sai Life Sciences declined to 14.73 per cent from 24.73 per cent. Shares of Sai Life Sciences rose 5.03 per cent to close at Rs 765.85 apiece on the BSE. In December last year, Sai Life Sciences raised Rs 3,043 crore through its initial public offering and the shares of the company made a stellar debut on the bourses. Sai Life Sciences provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical innovator companies and biotechnology firms.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store